ORGANIZATION
Kenporen Proposes Excluding OTC-Like Pollinosis Drugs from Health Coverage, Expecting Annual Savings of 60 Billion Yen
The National Federation of Health Insurance Societies (Kenporen) announced on August 23 its proposals for the FY2020 medical fee revision, calling for OTC-like ethical drugs for the treatment of pollinosis to be excluded from insurance coverage. Kenporen explained its proposals…
To read the full story
Related Article
ORGANIZATION
- Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
- FPMAJ Calls for Greater Support for Stable Drug Supplies in Honebuto Policy
May 22, 2026
- JPMA Exec Urges Broader Debate on Japan’s CEA System
May 22, 2026
- COVID-19 Vaccination Rates Fall as Out-of-Pocket Costs Rise: Jiji Survey
May 21, 2026
- Awareness of HPV Vaccination for Males Stands at 39.4%: Survey
May 21, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





